22,127 research outputs found
Branching fraction and CP asymmetry of the decays B+→K0Sπ+ and B+→K0SK+
No full textAn analysis of B+ → K0
Sπ+ and B+ → K0
S K+ decays is performed with the LHCb experiment. The pp
collision data used correspond to integrated luminosities of 1 fb−1 and 2 fb−1 collected at centre-ofmass
energies of
√
s = 7 TeV and
√
s = 8 TeV, respectively. The ratio of branching fractions and the
direct CP asymmetries are measured to be B(B+ → K0
S K+
)/B(B+ → K0
Sπ+
) = 0.064 ± 0.009 (stat.) ±
0.004 (syst.), ACP(B+ → K0
Sπ+
) = −0.022 ± 0.025 (stat.) ± 0.010 (syst.) and ACP(B+ → K0
S K+
) =
−0.21 ± 0.14 (stat.) ± 0.01 (syst.). The data sample taken at
√
s = 7 TeV is used to search for
B+
c
→ K0
S K+ decays and results in the upper limit ( fc · B(B+
c
→ K0
S K+
))/( fu · B(B+ → K0
Sπ+
)) <
5.8 × 10−2 at 90% confidence level, where fc and fu denote the hadronisation fractions of a ¯b
quark
into a B+
c or a B+ meson, respectively
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
No full text5-Fluorouracil (5-FU) plus cisplatin (C) can be considered a standard option for advanced gastric cancer (AGC). Irinotecan (Ir) and docetaxel (D) are active agents with no complete cross-resistance with C and 5-FU. Concomitant combination of Ir or D with C and 5-FU is feasible, but with substantial toxicities. A different way to include all active agents in first-line treatment of AGC may be to use them sequentially. We aimed to evaluate the activity and the safety profile of sequential chemotherapy with 5-FU-based doublets with C, Ir and D in the first-line treatment of AGC. We conducted a phase II study of first-line sequential chemotherapy in metastatic GC. Treatment consisted of 3 cycles of C + infused 5-FU and leucovorin (CFL) followed by 3 cycles of Ir + 5-FU/LV (IrFL) followed by 3 cycles of D + 5-FU/LV (DFL). Primary end-point was response rate. Forty-six patients were enrolled, median age 60 years, sites of disease (single/multiple) = 9/37, PS 0/1 = 27/19, gastric/gastro-oesophageal junction = 39/7. Median number of cycles was 9. Main grade 3-4 toxicities were neutropenia (37%), febrile neutropenia (2%), diarrhoea (4%), stomatitis (9%). Response rate after the planned 9 cycles was 45% (15 partial and 5 complete responses among 43 evaluable patients). Median PFS and OS: 6.8 and 11.1 months, respectively. This sequential treatment is feasible with a favourable safety profile and produced encouraging results in terms of activity and efficacy
A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer
No full textThe aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients. Consecutive cohorts of 6 patients were given 5-FU and FA infusions from 10.00 p.m. to 10.00 a.m. with peak delivery at 4.00 a.m. by means of a multichannel programmable pump. The FA dose was always the same (150 mg/m(2)/d). For the first cohort, the 5-FU dose level was 600 mg/m(2)/d at the first course, escalated by 100 mg/m(2) for each subsequent cohort. Intrapatient dose was also escalated by 100 mg/m(2) if toxicity was less than grade 2. The courses were repeated every 3 weeks. Thirty-four patients (17 previously treated) received a total of 154 courses. Dose-limiting toxicity consisted of stomatitis and diarrhoea. No significant haematological, cutaneous or cardiac toxicity was encountered. The MTD of 5-FU was reached at the fourth level (first course at 900 mg/m(2)/d equal to 4500 mg/m(2)/course) with 5-FU increased to 1100 mg/m(2)/d (5500 mg/m(2)/course) in 4 patients. The received 5-FU dose intensity (DI) over the first 3 courses at this level was 1318 mg/m(2)/week. Thirty-three patients were assessed for response. An objective response was achieved in 1 out of the 13 previously-treated and in 8 out of the 20 previously-untreated patients. The chronomodulated infusion of 5-FU at a dose of 900 mg/m(2)/d, together with FA at 150 mg/m(2)/d for 5 days, was safely delivered to outpatients with metastatic colorectal cancer. The low toxic profile and activity of this regimen in previously untreated patients deserves further exploration for the treatment of 5-FU-sensitive tumours. (C) 1997 Elsevier Science Ltd
Datasets for release study, swelling study, FTIR and SEM image for 5-FU loaded alginate microbeads
No full textATR-FTIR spectra of (a) 5-FU, (b) sodium alginate, (c) Tween 80, (d) calcium Percentage swelling index of 5-FU microbeads in HCl (Mean 土 SD, n=3). Percentage swelling index of 5-FU microbeads in phosphate buffer (Mean 土 SD, n=3). Cumulative percentage drug released of 5-FU microbeads in SGF (Mean ± SD, n=3). Cumulative percentage drug release of 5-FU microbeads in SIF (Mean ± SD, n=3).THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV
Corynoneura aggeris Fu & Wang & Fang & Xiao & Fu & Lin 2020, sp. n.
No full textCorynoneura aggeris Fu, sp. n. Fig. 1 Type material. Holotype male (NKU: A13I50), CHINA: Zhejiang Province, Hangzhou City, Changhua County, Qingliangfeng National Nature Reserve, 121°9′53″E, 30°17′49″N, a.s.l. 1100–1400 m, 12.V–20.VI.2012, malaise trap, leg. Rui Guo. Etymology. From Latin, aggeris, heap, mound, referring to transverse sternapodeme curved between U- and V-shaped, peak like a small mound. Diagnostic characters. The male imago is characterized by having an antenna with eight flagellomeres, AR 0.42; superior volsella small triangular, and anteromedially fused; inferior volsella narrowed, and placed caudally of gonocoxite; transverse sternapodeme narrow and without oral projection; the attachment point placed lateral sternapodeme is very small. Description. Adult male (n = 1). Total length 0.97 mm. Wing length 0.60mm. Total length/wing length 1.61. Wing length/profemur length 3.02. Coloration. Head and thorax dark brown. Legs pale yellow. Abdomen yellow brown. Head. Antenna with eight flagellomeres, AR 0.42. Ultimate flagellomere 95 µm long, slightly expanded apically, with ca. ten apical sensilla chaetica (Fig. 1B). Tentorium 113 µm long; 15 µm wide. Length of palpomeres (in µm): 15; 13; 15; 23; 45. Palpomere 5/3 ratio: 3.0. Thorax. Dorsocentrals 4. Scutellum with 2 setae. Wing (Fig. 1A). VR 3.2. Cu/wing length 0.60; C 160 µm long; Cu 360 µm long; wing width/wing length: 0.48. Costa with 8 setae. Legs. Fore trochanter with dorsal keel. Spurs of fore tibia 23 µm long, of mid tibia 10 µm long and 8 µm long, and spurs of hind tibia 38 µm long and 12 µm long. Width at apex of fore tibia 20 µm, of mid tibia 15 µm, of hind tibia (a) 40 µm. Width of hind tibia 1/3 from apex (d) 25 µm, elongation length (b) 30 µm, length of maximum thickening (c 1) 55 µm, total length of thickening (c 2) 80 µm; a/d 1.4; b/d 1.2; c 1 /d 2.2; c 2 /d 3.2. Hind tibia expanded, with comb of 16 setae, one seta near spur strongly S-shaped (Fig. 1C). Lengths and proportions of legs as in Table 1. Hypopygium (Fig. 1 D-E). Tergite IX and laterosternite IX without long seta. Tergite IX medially incurved, and pair of low caudal mounds with many setae on each side. Superior volsella undeveloped, and anteromedially fused. Inferior volsella with many glandular setae, along the inner margin of gonocoxite and placed caudally. Phallapodeme scalpel-like, apex slightly curved, 32 µm long, without obvious projection, and join with sternapodeme placed caudally. Transverse sternapodeme very narrow, curved between U- and V-shaped. Lateral sternapodeme with small attachment point placed and directed caudally. Gonostylus straight, 25 µm long; megaseta 2 µm long. HR 2.32; HV 3.88. Remarks. This species is similar to Corynoneura makarchenkorum Krasheninnikov, 2012 by having the same shape of the transverse sternapodeme and phallapodeme, but can be separated from the latter by the antenna with eight flagellomeres, AR 0.42; gonostylus straight in C. aggeris sp. n., while C. makarchenkorum has the antenna with 12 flagellomeres, AR 0.92–1.00, and apically curved gonostylus.Published as part of Fu, Yue, Wang, Xin-Hua, Fang, Xiang-Liang, Xiao, Yun-Li, Fu, Jun & Lin, Xiao-Long, 2020, Corynoneura Winnertz (Diptera, Chironomidae, Orthocladiinae) from Zhejiang Province, China, pp. 83-96 in Zootaxa 4890 (1) on pages 84-85, DOI: 10.11646/zootaxa.4890.1.4, http://zenodo.org/record/430156
EpCAM Aptamer Activated 5-FU-Loaded PLGA Nanoparticles in CRC Treatment; In vitro and In vivo study
No full textIn this study, EpCAM aptamer-activated nanoparticles (Ap-NPs) were synthesized to enhance treatment efficiency in colorectal cancer (CRC). PLGA [poly (D, L-lactide-co-glycolide)] copolymer was fabricated by conjugation of COOH-PEG-NH2 to PLGA-COOH through an EDC/NHS-mediated chemistry. Afterward, 5‐fluorouracil-loaded (FU) nanoparticles were prepared using the water/oil/water double emulsion solvent evaporation method. The in vitro cytotoxicity of formulations was evaluated using the MTT assay in HCT-116, CT-26, and HEK-293 cell lines. For in vivo study, tumor-bearing BALB/c mice were established by subcutaneous injection of CT-26 cell line. The results indicated that fabricated AP-FU-NPs had 101 nm size with a spherical surface, relatively homogeneously and, satisfactory encapsulation efficiency (83.93%). In vitro experiments revealed that Ap-FU-NPs had a superior in vitro cytotoxicity than both FU-NPs and free 5-FU in CT-26 and HCT-116 cells but, were significantly low toxic against HEK-293 cells relative to free 5-FU. Furthermore, in vivo results showed no significant hemolytic effect, hepatic and renal injury, or weight loss. After treatment of various animal groups with formulations, notable tumor growth delay was observed followed the order: Ap-FU-NPs The overall strategy of this study is summarized in Graphical Abstract. The present study was carried out in the three steps summarized: 1) synthesis and characterization. At first, PEG was conjugated to PLGA polymers by EDC/NHS chemistry method, then the resulting polymers were used to prepare PLGA-PEG NPs via the W/O/W technique. Finally, EpCAM Aptamers were attached to fabricated NPs. 2) In the second step cytotoxicity of formulated NPs was evaluated in vitro experiments in HEK-293, CT-26, and HCT-116 cell lines. 3) In the third step in vitro results further was investigated in CT-26 tumor-bearing BALB/c mice. “Created with BioRender.com.”</p
Corynoneura recta Fu & Wang & Fang & Xiao & Fu & Lin 2020, sp. n.
No full textCorynoneura recta Fu, sp. n. (Fig. 6) Type material. Holotype male (NKU: A13I58), CHINA: Zhejiang Province, Hangzhou City, Changhua County, Qingliangfeng National Nature Reserve, 121°9′53″E, 30°17′49″N, a.s.l. 1100–1400 m, 12.V.2012 – 20.VI.2012, malaise trap, leg. Rui Guo. Etymology. From Latin, rectus, straight, upright, referring to the inferior volsella with a right-angled corner. Diagnostic characters. The male imago is characterized by having an antenna with eight flagellomeres, AR 0.47; superior volsella separated, like rounded corner. Inferior volsella broad, with right-angle corner, along the inner margin of gonocoxite and placed medially. Description. Adult male (n = 1). Total length 1.0 mm. Wing length 0.63 mm. Total length/wing length 1.58. Wing length/profemur length 2.84. Coloration. Head and thorax dark brown. Legs yellowish. Abdomen yellow-brown. Head. Antenna with eight flagellomeres, AR 0.47, ultimate flagellomere 123 µm long, ultimate flagellomere slightly expanded apically, with about 10 apical sensilla chaetica (Fig. 6D). Tentorium and cibarial pump as in Fig. 6B, tentorium 125 µm long; 13 µm wide. Anterior margin of cibarial pump (Fig. 6B) strongly concave. Length of palpomeres (in µm): 15; 13; 15; 20; 38. Palpomere 5/3 ratio: 2.5. Thorax (Fig. 6E). Dorsocentrals 4. Scutellum with 2 setae. Prealars 1. Wing (Fig. 6A). C 170 µm long; wing width/wing length: 0.42. Costa with 7 setae. Legs. Fore trochanter with dorsal keel. Spurs of fore tibia 15 µm long, spur of hind tibia 13 µm long and 25 µm long. Width at apex of fore tibia 23 µm, of hind tibia (a) 18 µm. Width of hind tibia 1/3 from apex (d) 18 µm, elongation length (b) 37 µm, length of maximum thickening (c 1) 50 µm, total length of thickening (c 2) 75 µm; a/d 2.06; b/d 2.06; c 1 /d 2.78; c 2 /d 4.17. Hind tibia expanded, with comb of 18 setae, one seta near spur strongly S-shaped (Fig. 6C). Lengths and proportions of legs as in Table 5. Hypopygium (Fig. 6 F-H). Tergite IX and laterosternite IX without long setae. The margin of tergite IX straight, medially not curved. Superior volsella anteromedially separated, like rounded corner. Inferior volsella broad, with many glandular setae and right-angle corner, along the inner margin of gonocoxite and placed medially. Phallapodeme apical slightly curved, 38 µm long, joint with sternapodeme placed caudally. Transverse sternapodeme 15 µm wide. Small attachment point of lateral sternapodeme with phallapodeme placed and directed caudally. Gonostylus slightly curved tapering, 25 µm long, megaseta 3 µm long. HR 2.52; HV 4.0. Remarks. The new species is similar to Corynoneura tertia Makarchenko et Makarchenko, 2010 by having antenna with 8 flagellomeres, sternapodeme curved into a U-shape, and phallapodeme low, join with sternapodeme placed caudally. The new species can be separated from the latter by the phallapodeme being slightly curved, the inferior volsella broad with a right-angled corner, while in C. tertia the phallapodeme is relatively longer and obviously curved, the inferior volsella is long and narrow as is the inner margin of the gonocoxite.Published as part of Fu, Yue, Wang, Xin-Hua, Fang, Xiang-Liang, Xiao, Yun-Li, Fu, Jun & Lin, Xiao-Long, 2020, Corynoneura Winnertz (Diptera, Chironomidae, Orthocladiinae) from Zhejiang Province, China, pp. 83-96 in Zootaxa 4890 (1) on pages 92-93, DOI: 10.11646/zootaxa.4890.1.4, http://zenodo.org/record/430156
(1 -> 3)-beta-D-Glucan oligosaccharides monomers purification and its H2O2 induction effect study
No full textIn order to produce highly purified (1 -> 3)-beta-D-glucan oligosaccharides ((1 -> 3)-beta-D-GOS) monomers, a hydrophilic interaction liquid chromatography (HILIC) system with X-Amide stationary phase was performed. Nine (1 -> 3)-beta-D-GOS monomers with degree of polymerization (DP) from 2 to 10 were successfully separated. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) demonstrated that these monomers were with high purity. Furthermore, a hydrogen peroxide (H2O2) online detection method was established to monitor H2O2 releases in tobacco cells. This is the first report on nine consecutive (1 -> 3)-beta-D-GOS monomers purification and its effect upon H2O2-releasing in plants. Itwas found that (1 -> 3)-beta-D-GOS monomers with higher DP induced stronger defense responses in plants, which will pave the way for elucidating the relationship between (1 -> 3)-beta-D-GOS and biological activities. (C) 2015 Elsevier B.V. All rights reserved
Raw data for release study, swelling study, FTIR and SEM image for 5-FU loaded alginate microbeads
No full textATR-FTIR spectra of (a) 5-FU, (b) sodium alginate, (c) Tween 80, (d) calciumPercentage swelling index of 5-FU microbeads in HCl (Mean 土 SD, n=3).Percentage swelling index of 5-FU microbeads in phosphate buffer (Mean 土 SD, n=3).Cumulative percentage drug released of 5-FU microbeads in SGF (Mean ± SD, n=3).Cumulative percentage drug release of 5-FU microbeads in SIF (Mean ± SD, n=3).THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV
Gemcitabine: Progress in the treatment of pancreatic cancer
No full textUnresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor. Treatment with single-agent gemcitabine achieved clinical benefit and symptoms improvement in 20-30% of patients. While 1-year survival was observed in 2% of 5-fluorouracil (5-FU)-treated patients, it was raised to 18% by single-agent gemcitabine. Good treatment tolerability and low incidence of side effects are clear advantages of single-agent gemcitabine. Improvement of efficacy is, however, expected from combination treatment. Gemcitabine and cisplatin given as first-line treatment in three studies achieved a median survival of 7.4-8.3 months. One-year survival was raised to 28% as reported in one study. Comparable activity was obtained by a combination of gemcitabine with 5-FU. Nine studies using gemcitabine in combination with standard-dose or high-dose 5-FU reported a median survival ranging from 5.5 to 13 months. Notwithstanding these promising results, recommendations regarding palliative chemotherapy of pancreatic cancer remain tentative and still need confirmation by presently ongoing phase III trials. Inclusion of pancreatic cancer patients into clinical trials should be a major goal. Outside clinical trials, patients should present with an adequate PS (Karnofsky-performance index greater than or equal to 70) to qualify for chemotherapy. Copyright (C) 2001 S. Karger AG, Basel
- …
